Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and Charles River Laboratories (CRL) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks w ...

公司业绩 - Charles River Laboratories International, Inc. (CRL)将于2024年5月9日在市场开盘前公布第一季度业绩[1] - 上一季度公司每股调整后盈利为2.46美元，超过Zacks Consensus Estimate 2.9%[2] 市场趋势 - 研究模型和服务(RMS)市场部分受到全球对研究模型和相关服务的持续需求的推动[3] - 公司计划通过适度提价来推动大部分增长，预计中国市场对紧凑型模型和相关服务的需求将持续强劲[4]

Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Charles River Laboratories (CRL) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revis ...

A month has gone by since the last earnings report for Charles River Laboratories (CRL) . Shares have added about 6.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Charles River due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Charles River Q4 Earnings Beat, Mar ...

Navega Therapeutics - Navega Therapeutics 利用其 AI 功能的锌指表观基因调控技术，研究治疗罕见疾病如小纤维神经病变和原发性红热病所致慢性疼痛的疗法[2] - Navega Therapeutics 开发的非阿片类基因疗法用于慢性疼痛，可能被用于治疗神经病性和炎症性疼痛，因为超过 1700 万美国公民患有高影响力慢性疼痛[3] Charles River Laboratories International, Inc. - Charles River Laboratories International, Inc. 与 Navega Therapeutics 签署了 AAV9 生产计划协议，将为 Navega Therapeutics 提供 Charles River 的合同开发和制造能力，以及咨询服务，生产 AAV 基因疗法候选药 NT-Z001 用于一期临床试验[1]

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z0 ...

公司演讲 - Charles River Laboratories International, Inc. (NYSE: CRL)将在巴克莱第26届全球医疗保健大会上进行演讲[1] - 演讲将通过Charles River网站的投资者关系部分提供现场网络直播[2] - Charles River为制药和生物技术公司、政府机构和领先的学术机构提供必要产品和服务，加速其研究和药物开发工作[3]

强劲医疗股票 - 三家医疗股票值得关注，包括强劲的Johnson & Johnson (JNJ)[2] - JNJ股票是一个完美的防御性选择，具有稳定的股价和丰厚的股息[3] 生物技术行业发展 - Charles River Laboratories (CRL)在生物技术行业发展迅速，为临床试验提供实验标本[7] - Charles River参与了80%获得FDA批准的药物的开发，具有稳健的业绩增长[9] 医疗器械公司前景 - Medtronic (MDT)是全球最大的医疗器械公司之一，股价低迷但前景看好[12] - MDT股票在最近的财年Q3表现优异，业务各领域数据持续改善，前景乐观[16]

WILMINGTON, Mass. and OKLAHOMA CITY, Feb. 29, 2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreement with Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in pharma services, to offer Wheeler Bio's Portable CMC® (Chemistry, Manufacturing and Controls) platform to Charles River Laboratory clients. The collaboration is designed to enable a swift transition from pre-clinical stages directl ...

合作关系 - Charles River Laboratories International, Inc.（CRL）最近宣布与Wheeler Bio建立战略合作伙伴关系，提供客户使用Wheeler的Portable CMC平台，加速从临床前活动到首次人体临床试验的过渡[1] - 合作将结合Charles River在抗体发现服务、安全和分析方面的行业领先经验与Wheeler的Portable CMC平台，加速治疗性发现到IND提交时间表[6] Wheeler Bio - Wheeler Bio是一家生物制造先驱，通过其Portable CMC技术平台简化了药物发现和临床制造之间的路径，为创新者提供了更快地实现临床里程碑的新途径[3]